Zeo ScientifiX, Inc.
Zeo ScientifiX, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on biological therapeutics for degenerative diseases and regenerative medicine. Its portfolio includes products derived from ethically sourced birth tissue, amniotic fluid, exosomes, Wharton's Jelly matrix, and an autologous biologic platform, with operations centered on manufacturing, commercialization, and related clinical support services.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueProprietary biologic products derived from birth tissue, amniotic fluid, and related sources.
Patient-specific PPX™ processing and service platform using a patient's own blood.
cGMP production, release testing, and related laboratory support for biologic products.
Customers
Zeo ScientifiX sells primarily to healthcare providers, including doctors and clinics that administer regenerative medicine and aesthetic biologic products. Its commercial model also depends on distributors and, in collaboration settings, clinical and manufacturing partners that support product access and delivery.
Doctors, clinics, and treatment centers that purchase biologics for in-office use and patient care.
Providers focused on degenerative disease, wound care, pain, and regenerative applications.
Clinics using allogenic aesthetic biologic products for cosmetic and related procedures.
Channel partners that market and distribute the company's products to providers.
Partners involved in manufacturing, regulatory development, and site management for specific programs.
Strategy
Zeo ScientifiX is focused on expanding commercialization of its biologic portfolio while continuing product development and clinical work in regenerative medicine. The company also appears to be building channel reach through in-house sales, distributors, and collaboration-based manufacturing and market-access arrangements.
The business depends on provider adoption and repeat use of its biologic products.
New products can broaden the addressable market and reduce reliance on a narrow product mix.
Partnerships can provide manufacturing capacity, regulatory support, and commercial reach.
Geography
The company is headquartered in Davie, Florida and operates through U.S.-based laboratory and commercial activities. Its disclosures indicate a customer and distribution network across the United States, with additional worldwide reach through its broader provider base and collaboration activity.
Risks
The company faces substantial going-concern, funding, and execution risk because its business requires ongoing capital, regulatory compliance, and successful commercialization of biologic products. It also operates in a competitive and highly regulated regenerative medicine market where product acceptance, intellectual property protection, and supply continuity can materially affect results.
- Going-concern and financing dependenceImpact: CriticalLikelihood: High
Operations and development require additional capital, and funding may be costly or unavailable.
Exposure: Corporate liquidity and ongoing operations
- Regulatory and compliance riskImpact: HighLikelihood: High
Products are biologics subject to FDA oversight, HCT/P enforcement, and cGMP requirements.
Exposure - Competitive pressureImpact: HighLikelihood: High
Larger competitors may have stronger brands, capital, and distribution, pressuring pricing and share.
Exposure: Allogenic biologics and regenerative medicine products
- Internal control weaknessesImpact: HighLikelihood: High
Material weaknesses can impair financial reporting reliability and investor confidence.
Exposure: Financial statements and disclosure controls
- Supply concentration and third-party dependenceImpact: MediumLikelihood: Medium
Raw materials and supplies are sourced from unaffiliated laboratories and could be disrupted.
Exposure: Manufacturing continuity and product availability
- Intellectual property protectionImpact: MediumLikelihood: Medium
Commercial success depends on patents and proprietary processing techniques.
Exposure
Accounting
Judgemental itemsPPX™ service revenue and product sales may be recognized differently and shift period results.
Impact: Affects revenue timing, gross margin, and comparability
Reported G&A includes significant non-cash compensation to advisors, consultants, and staff.
Impact: Can materially increase operating expenses
Management's assumptions affect whether recorded assets are recoverable.
Impact: May lead to impairment or write-down risk
Material weaknesses increase the risk of misstatement in estimates and reported balances.
Impact: Affects reliability of financial statements
Similar listed companies
Publicly listed companies with a comparable business focus.
Zivo Bioscience, Inc.
ZIVO · Biological Products, (No Diagnostic Substances)
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
eXoZymes Inc
EXOZ · Biological Products, (No Diagnostic Substances)
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
Sangamo Therapeutics, Inc
SGMOQ · Biological Products, (No Diagnostic Substances)
Sangamo Therapeutics is a U.S.-based genomic medicine company focused on developing therapies and enabling technologies built around zinc finger biology,…
Last updated: 24/09/2026